Sotyktu Begins Defining a New Oral Treatment Segment in Psoriatic Arthritis, According to Spherix Global Insights Launch Research

Summary

Spherix Global Insights launch research indicates that Sotyktu (a TYK2 inhibitor) is beginning to establish a new oral treatment segment in psoriatic arthritis based on early physician experience. The drug may expand treatment options beyond traditional positioning with potential implications for competitive dynamics in the market.